Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

Next Previous
Trial Profile

A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms EMBRACE
  • Sponsors Amgen; Celgene International SARL

Most Recent Events

  • 01 Feb 2023 Primary endpoint (Percentage of Participants Who Achieved a 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 [ Time Frame: Baseline and week 16 ]) has been met, according to Results published in the Journal of the European Academy of Dermatology and Venereology.
  • 01 Feb 2023 Results published in the Journal of the European Academy of Dermatology and Venereology
  • 30 Aug 2022 According to an Amgen media release, 16-Week Subgroup Analysis will be presented at the 31st European Academy of Dermatology and Venereology (EADV) 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top